Researchers sought to examine Life’s Essential 8 trajectories and their relationship with risk for stroke in patients in China. A study was conducted to assess the safety and efficacy of finerenone ...

The mineralocorticoid receptor antagonist did not reduce primary outcomes in the CLEAR SYNERGY trial, but there was a ...

The FINEARTS-HF trial offered novel clinical insights as one of the few cardiovascular trials to feature such a great proportion of female participants.

Proposed in the early 1980s as a solution for managing complications of portal hypertension, the percutaneous creation of ...

Follow-up results for the FINEARTS-HF trial focused on specific results for women and men, hyperkalemia risk, and an analysis ...

In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone, a nonsteroidal mineralocorticoid ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

In the Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF), finerenone reduced the risk of the primary end point similarly in women and ...

In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, resulted in more frequent hyperkalemia and less ...

The improved engagement with HF patients intended to optimize GDMT was very modest, but did lead to increased use of MRAs.

Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...

Objectives This study aimed to evaluate the efficacy and safety of finerenone, a selective, non-steroidal mineralocorticoid receptor antagonist, on cardiovascular and kidney outcomes by age and/or sex ...